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Abstract  We herein report a case of lung metastasis from breast cancer combined with primary lung cancer.  A 
59-year-old female had received mastectomy 5 years ago, and underwent adjuvant chemotherapy with trastuzumab and 
anastrozole.  Chest computed tomography revealed nodules in right lobe of lung.  She underwent partial resection through 
video-assisted thoracoscopic surgery, and metastatic breast cancer and primary lung cancer were recognized on pathological 
diagnosis.  Two years later after chemotherapy and exemestane with trastuzumab, she was pointed out lung cancer 
recurrence and has been receiving chemotherapy.  When nodules are removed and diagnosed as lung metastasis combined 
with primary lung cancer, additional treatment should be considered depending on the prognosis of each disease. 
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Introduction 
 
Pulmonary nodules that appear in a patient with 
prior malignancy may be a metastasis or a second 
primary lung cancer [1].  Advances in computed 
tomography (CT) have made it possible to detect 
small tumors of the lung [2], however, the differential 
diagnosis of metastasis or primary lung cancer is 
usually difficult for such small nodules.  The lung is 
a common site of metastasis in patients with breast 
cancer, with 12 % of breast cancer patients found to 
have metastatic lesions in the lung [3].  Treatment 
strategies for the pulmonary nodules vary depending 
on their diagnosis.  Differential diagnosis of 
metastasis and primary lung cancer is therefore 
crucial for the planning of optimal treatment of 
patient with a history of breast cancer.  We report a 
case of lung metastasis of breast cancer combined 
with primary lung cancer.  
 
Case report 
 
A 59-year-old non-smoking Japanese woman had 
received modified radical mastectomy for her left 
breast carcinoma 5 years ago.  No sentinel nodal 
metastasis (0/1) was noted.  The estrogen receptor 
(ER) and progesterone receptor (PgR) are positive, 
and human epidermal growth factor receptor type 2 
(HER2) shows over-expression (3+) on the resected 
specimen.  She underwent adjuvant chemotherapy 
w i t h  3  c o u r s e s  o f  i n t r a v e n o u s  e p i r u b i c i n , 
cyclophosphamide and fluorouracil followed  by 3 
c o u r s e s  o f  d o c e t a x e l  w i t h  t r a s t u z u m a b  a n d 
anast rozo le ,  an aro matase  inhib i to r.   No loca l 
irradiation was administered before.  The clinical 
course was smooth postoperatively, until pulmonary   
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nodules were accidentally found on the chest CT.  
Chest CT revealed 0.8 cm nodule with smooth margin 
in anterior segment of right lower lobe of lung (S8) 
and 0.7 cm nodule in the anterior segment of right 
upper lobe (S3) (Fig.1).  The carcino -embryonic 
antigen (CEA) and neuron specific enolase (NSE) 
levels were within normal range.  Pulmonary 
primary carcinoma or metastasis is highly suspected 
and thus she underwent partial resection through 
video-assisted thoracoscopic surgery (VATS) and 
open.  Metastatic breast cancer on S8 and primary 
lung cancer (small cell carcinoma) on S3 were 
recognized on intraoperative pathological diagnosis, 
and she underwent right S3 segmentectomy and 
mediastinal lymph nodes dissection.  The 
immunohistological staining showed that the tumor 
of S8 was positive gross cystic disease  fluid 
protein-15 (GCFD-15) positive, ER positive, PgR 
negative and HER2 positive (Fig.2), the tumor of S3 
was thyroid transcription factor -1 (TTF-1) and neural 
cell adhesion molecule (NCAM) positive (Fig.3).  
She underwent postoperatively chemotherapy wit h 4 
courses of cisplatin and etoposide, and received 
exemestane and trastuzumab treatment.  Two years 
later of re-operation, she was pointed out lung cancer 
recurrence and has been receiving chemotherapy of 
cisplatin and irinotecan, and she was transferred to 
palliative care due to the disease progression  after 2 
years later of lung cancer recurrence.  
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The histological identity of pulmonary lesions in 
breast cancer patients has major therapeutic 
implications, since the appropriate oncologic 
treatment differs significantly depending on the 
possibilities.  Biological characteristics of ER, PgR 
and HER2 are very important for predicting the 
efficacy of therapy and patients ’ prognosis.  Biopsy 
for the reassessment of these markers at the time of 
disease recurrence is strongly recommended [4].  
Certain radiographic or clinical characteristics have also 
been proposed in the literature to help distinguish metastatic 
lesion from primary lung tumor.  Metastatic lung nodules 
are often described as spheric or ovoid, well circumscribed, 
and located in the periphery [5, 6], while primary lung cancer 
is more commonly associated with irregular borders and 
associated linear densities [7]. 
Pulmonary nodules that appear in patients who 
underwent mastectomy for the breast cancer may not 
always be pulmonary metastases, several studies 
reported the probability of having primary lung 
cancer among all solitary nodules appearing after 
mastectomy to range between 12 % and 48 % [8,  9]. 
The decision-making in the treatment should be made 
only after the pathologic diagnosis is confirmed.  
When nonsurgical diagnosis such as transbronchial 
biopsy and needle biopsy through the guidance of CT 
fails to reveal a pathological diagnosis, VATS should 
be considered as an option for the diagnosis [8, 9].  
VATS has been demonstrated to be a useful procedure  
in peripheral pulmonary nodules, but in quite 20% of  
ca ses  th e  d eep  lo ca t io n  o f  the  no d ule  i n  th e  
Fig. 1  Computed tomography of the chest showed tumors  
There in the right lobe measuring 0.7 cm and 0.8 cm, respectively (left; S3, right; S8) 
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p a r e n c h y ma  r e q u i r e s  o p e n  p r o c e d u r e  f o r  i t s 
l o ca l i za t io n  a n d  co mp le t e  r e s ec t io n  [ 1 0 ] .  T h e 
d i s t i n c t i o n  o f  a  p r i ma r y  l u n g  c a n c e r  f r o m a 
metastatic lesion is important, because the treatment 
a n d  p r o g n o s i s  d i f f e r  f o r  p a t i e n t s  w i t h  t h e s e 
m a l i g n a n c i e s .   I n  h i s t o l o g i c a l  s e c t i o n s ,  t h e 
e x i s t e n c e  o f  a c i n i ,  l e p i d i c  g r o w t h ,  n u c l e a r 
pseudoinclusions, and scar favor the diagnosis of 
primary lung adenocarcinoma; on the other hand, 
comedo-necrosis, solid nests, trabecular architecture,  
and cribriform growth can be identified in metastatic 
breast carcinoma [11].  Such a distinction can also  
 
 
 
 
 
 
be achieved by detection of special markers on the 
histological specimens, such as GCDFP -15 or TTF-1. 
GCDFP-15 is a marker for breast carcinoma [12,  13].  
Overall, 55-72% of breast carcinoma studied stained 
positively for GCDFP-15.  TTF-1 protein that 
regulates transcription of genes, and thus it is used as 
a marker to determine if a tumor arises from the lung 
or thyroid [14].  TTF-1 is usually positive in 
pulmonary adenocarcinoma or small cell carcinoma.  
NCAM is a cell-surface sialoglycoprotein of the 
immunoglobulin family involved in cell -to-cell 
interactions during neural development [15].  NCAM 
Fig. 2  The pathological findings of the tumor of S8.  The immunohistological 
staining showed that the cells were GCFD-15 positive, ER positive, PgR negative and 
HER2 positive. 
a) H & E stain (×40), b) GCFD-15 (×200), c) ER (×200) , d) PgR (×200), e) HER2 (×200)  
a) 
b) 
c) 
d) 
e) 
Fig. 3  The pathological findings of the tumor of S3.  The immunohistological 
staining showed that the cells were TTF-1 and NCAM positive. 
a) H & E stain (×40), b) TTF-1 (×200), c) NCAM (×200)  
 
b) 
a) c) 
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is expressed in natural killer (NK) cells and 
NK-derived malignant neoplasms, but it also is found 
in many neural and neuroendocrine tissues and in 
several neuroendocrine tumors (carcinoid tumors, 
paragangliomas, small cell carcinomas) [16]. 
Pulmonary nodules in patients with prior breast 
cancer were usually regarded as metastatic lesions. 
However the possibility of primary lung cancer still 
cannot be excluded.  When nodules are removed and 
diagnosed as lung metastasis combined with primary 
lung cancer, additional treatment should be 
considered following careful reassessment of CT 
images and the size and pathological features of the 
tumor.  
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